Characteristics of probable COVID-19 Omicron symptoms in Sanglah hospital Denpasar
Keywords:Coronavirus disease 2019, Omicron, SGTF
Background: Omicron (B.1.1.529) is a variant of COVID-19 which is first reported from Gauteng Province, South Africa in November 2021. This variant was considered the fifth variant of concern (VOC) by the world health organization (WHO) due to its much faster transmission but with milder clinical manifestations than other COVID-19 variants.
Methods: This retrospective cross-sectional descriptive study was conducted in Sanglah general hospital, Denpasar, Bali in March 2022. Subjects of this study were all patients who were diagnosed with probable COVID-19 Omicron by having a positive S-gene target failure (SGTF) of a reverse transcriptase polymerase chain reaction (RT-PCR) test in Sanglah general hospital from January to February 2022. All subjects must age 18 years old or older. Data on patient characteristics and clinical manifestations were obtained from medical record data and analyzed using statistical package for service solution (SPSS) for windows version 25.
Results: A total of 79 probable COVID-19 Omicron patients were analyzed in this study. Most of them were elderly who age more than 65 years old (30.4%), male (50.6%), and work as an entrepreneur (24.1%). The majority of probable COVID-19 Omicron patients were symptomatic (89.9%) with the most common clinical manifestation found was cough (54.9%). Other clinical manifestations found were shortness of breath (50.7%), fever (38.0%), fatigue (21.1%), runny nose (11.3%), sore throat (8.5%), nausea and vomit (2.8%), headache (1.4%), diarrhea (1.4%), and anosmia (1.4%).
Conclusions: The clinical manifestations of probable COVID-19 Omicron patients vary but most of them were classified as mild symptoms.
Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo CW, Susilo A et al. Pedoman Tatalaksana COVID-19. 4th ed. Jakarta: Perhimpunan Dokter Paru Indonesia (PDPI). 2022.
Menteri Kesehatan RI. Pedoman Pencegahan dan Pengendalian Coronavirus Disease 2019 (COVID-19). Jakarta: Kementrian Kesehatan Republik Indonesia. 2020.
Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586-90.
Young B, Fong S-W, Chang ZW, Tan K Sen, Rouers A, Goh YS et al. Comparison of the clinical features, viral shedding and immune response in vaccine breakthrough infection by the Omicron and Delta variants. Researchsquare. 2022;1-23.
CNN Indonesia. First Case Omicron di Republik Indonesia yang tak dilaporkan. 2021 Available at: https://www.cnnindonesia.com/nasional/20211223083554-20-737635/menkes-jelaskan-first-case-omicron-di-ri-yang-tak-dilaporkan-resmi. Accessed on 26 April 2022.
Baker JM, Nakayama JY, O’Hegarty M, McGowan A, Teran RA, Bart SM et al. SARS-CoV-2 B. 1.1. 529 (Omicron) variant transmission within households-four US jurisdictions, November 2021-February 2022. Morb Mortal Wkly Rep. 2022;71(9):341.
Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes among patients infected with Omicron (B. 1.1. 529) SARS-CoV-2 variant in southern California. MedRxiv. 2022;1-10.
Espenhain L, Funk T, Overvad M, Edslev SM, Fonager J, Ingham AC et al. Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021. Eurosurveillance. 2021;26(50):2101146.
Pivonello R, Auriemma RS, Pivonello C, Isidori AM, Corona G, Colao A et al. Sex disparities in COVID-19 severity and outcome: are men weaker or women stronger? Neuroendocrinology. 2021;111(11):1066-85.
Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022;399(10335):1618-24.
Kim M-K, Lee B, Choi YY, Um J, Lee K-S, Sung HK, et al. Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea. J Korean Med Sci. 2022;37(3).
Chavda VP, Apostolopoulos V. Omicron variant (B. 1.1. 529) of SARS-CoV-2: Threat for the elderly? Maturitas. 2022;158:78-81.
Lan FY, Wei CF, Hsu YT, Christiani DC, Kales SN. Work-related COVID-19 transmission in six Asian countries/areas: a follow-up study. PLoS One. 2020;15(5):e0233588.